UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Last trade$92.47
Day change+$0.03 (+0.03%)
Day range$91.77 – $95.33
Volume218,451
Market cap$5.09B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.09B
Price / earnings
25.97×
Price / book
3.71×
Price / sales
3.38×
EV / sales
3.2×
EV / EBITDA
22.17×
Profitability
Earnings per share
$3.56
Return on assets
7.23%
Return on equity
14.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.22×
Current ratio
3.04×
Quick ratio
2.54×
Cash ratio
1.58×
Cash flow
Price / cash flow
21.41×
Price / free cash flow
39.47×
Free cash flow
$129.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LIVN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$393.15M
$390.59M
$362.26M
$360.92M
$357.75M
$352.52M
$316.86M
$321.83M
Cost of revenue
$128.1M
$116.92M
$118.51M
$121.15M
$112.9M
$113.54M
$100.6M
$107.46M
Gross profit
$265.05M
$273.67M
$243.75M
$239.77M
$244.86M
$238.99M
$216.25M
$214.37M
Selling, general and administrative
$154.93M
$158.13M
$143.57M
$143.37M
$138.52M
$137.78M
$129.15M
$130.64M
Research and development
$47.69M
$53.66M
$58.7M
$52.12M
$48.58M
$47.19M
$37.88M
$43.31M
Total operating expenses
$236.63M
$224.19M
$202.28M
$197.2M
$190.84M
$184.81M
$528.03M
$177.35M
Operating income
$28.43M
$49.48M
$41.47M
$42.58M
$54.01M
$54.18M
-$311.78M
$37.02M
Interest expense
-$7.95M
-$7.18M
-$8.29M
-$10.86M
-$10.86M
-$14.93M
-$15.29M
-$15.77M
Income before taxes
$46.77M
$18.48M
$27.49M
$27.63M
$33.91M
$33.32M
-$315.65M
$56.48M
Income taxes
$12.4M
-$90.2M
$4.34M
-$3.28M
$7.11M
$6.15M
$11.66M
$589K
Net income
$34.29M
$108.57M
$22.29M
$30.91M
$26.78M
$27.16M
-$327.32M
$55.89M
Net income attributable to common shareholders
$34.29M
$108.57M
$22.29M
$30.91M
$26.78M
$27.16M
-$327.32M
$55.89M
EBITDA
$43.91M
$64.9M
$54.33M
$54.65M
$66.26M
$65.5M
-$301.14M
$47.69M
Basic earnings per share
$0.62
$1.98
$0.41
$0.57
$0.49
$0.50
-$6.01
$1.03
Diluted earnings per share
$0.11
$1.93
$0.40
$0.57
$0.49
$0.50
-$6.01
$1.01
Recent news
Company coverage with links to the original publishers.
The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.
LivaNova (LIVN) reported Q3 2026 earnings of $1.23 per share, beating consensus estimates of $1.03 and delivering a 19.42% surprise. Revenue reached $393.1 million, surpassing estimates by 3.43%. The company has outperformed market expectations for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries.
Waters Corporation reported Q3 2026 earnings of $4.1 per share, beating consensus estimates of $3.99, with revenues of $1.77 billion exceeding expectations by 0.81%. The company has consistently beaten estimates over the last four quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Waters shares have gained 18.4% year-to-date versus the S&P 500's 10.2% gain.
ClearPoint Neuro reported a Q3 loss of $0.24 per share, beating expectations of $0.32 loss, but missed revenue estimates with $12.08 million versus consensus. The company has underperformed the S&P 500 by 41% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.